1. Home
  2. CAAP vs TVTX Comparison

CAAP vs TVTX Comparison

Compare CAAP & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corporacion America Airports SA

CAAP

Corporacion America Airports SA

HOLD

Current Price

$25.11

Market Cap

4.5B

ML Signal

HOLD

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$57.24

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAAP
TVTX
Founded
1998
N/A
Country
Luxembourg
United States
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
5.3B
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
CAAP
TVTX
Price
$25.11
$57.24
Analyst Decision
Buy
Strong Buy
Analyst Count
3
13
Target Price
$26.73
$40.62
AVG Volume (30 Days)
185.9K
1.4M
Earning Date
05-21-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
92.89
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.80
$44.76
Revenue Next Year
$2.36
$35.51
P/E Ratio
$26.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.36
$15.03
52 Week High
$30.50
$60.10

Technical Indicators

Market Signals
Indicator
CAAP
TVTX
Relative Strength Index (RSI) 49.12 57.47
Support Level $24.78 $53.93
Resistance Level $26.76 $59.89
Average True Range (ATR) 0.66 2.58
MACD 0.04 -0.48
Stochastic Oscillator 61.62 55.36

Price Performance

Historical Comparison
CAAP
TVTX

About CAAP Corporacion America Airports SA

Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Share on Social Networks: